Today: 21 May 2026
Polestar (PSNYW) today: reverse stock split plan, wider Q3 loss, 9‑month revenue +49% — what it means for warrant holders (Nov 12, 2025)
12 November 2025
3 mins read

Polestar (PSNYW) today: reverse stock split plan, wider Q3 loss, 9‑month revenue +49% — what it means for warrant holders (Nov 12, 2025)

  • Reverse stock split planned to help retain Nasdaq listing after shares stayed under the $1 minimum bid price. Details on the ADS-to-ordinary-share ratio change will follow from the company.
  • Q3 2025 results: revenue rose 36% YoY to $748M, but net loss widened to $365M on pricing pressure, tariffs and residual value guarantees tied to U.S. leases.
  • Nine-month 2025 snapshot: revenue +48.8% to $2.17B; reported gross margin (34.5%) for 9M due to earlier impairment; Q3 gross margin (6.1%).
  • Liquidity & support: Company highlights $200M PIPE from a Li Shufu–controlled entity and $3.2B total in renewed/new facilities YTD, with covenants in compliance as of Sept. 30.
  • Nasdaq notice timeline: Polestar has until April 29, 2026 to regain the $1 minimum (ten consecutive trading days).

What happened today (Nov 12, 2025)

Polestar Automotive reported third‑quarter results and said it will execute a reverse stock split to address Nasdaq’s minimum bid requirement. Shares fell in early U.S. trading after the update, with Reuters noting an intraday drop of up to 17% as investors digested the combination of stronger revenue but deeper losses.

On the operations and finance side, Polestar’s press release shows Q3 revenue of $748M (+36% YoY) and a net loss of $365M, as higher costs (including tariffs) and weaker used‑EV values increased residual‑value guarantee charges in North America. For the first nine months of 2025, revenue climbed to $2.171B (+48.8%). The company reported a (34.5%) gross margin for 9M (reflecting a Q2 impairment on Polestar 3) and (6.1%) in Q3. Management underscored ongoing retail network expansion and cost‑efficiency measures.


Today’s market check (PSNYW & PSNY)

  • PSNYW (Polestar warrants):$0.2261 as of 14:46 UTC.
  • PSNY (common ADS):$0.6353 as of 15:37 UTC.

Prices are real‑time snapshots and will move as trading continues.


Reverse stock split: what warrant holders (PSNYW) should know

Polestar said it plans to change the ADS-to-ordinary‑share ratio via a reverse stock split; specifics (ratio, effective date, treatment of fractional shares) are “to be announced shortly.” In corporate actions like this, warrants are typically adjusted according to the terms of the warrant agreement (exercise price and/or warrant‑to‑share ratio) so that holders are neither advantaged nor disadvantaged purely by the split. Polestar has not yet published the warrant adjustment mechanics for PSNYW—watch for the company’s detailed notice and the depositary’s corporate action bulletin. Business Wire


Why it matters

  • Listing compliance: Nasdaq’s $1 bid price rule is binary. A reverse split can mechanically lift the per‑share price and restart the compliance clock. Polestar has until April 29, 2026 to get back above $1 for ten consecutive sessions (with a potential second 180‑day window thereafter).
  • Profit path vs. volume growth: Revenue is growing on higher volumes and a broader lineup, but margins remain negative, pressured by tariffs, pricing, and lease residuals—key variables to watch through 2026.
  • Funding and support: The $200M PIPE and renewed credit lines signal continued backing from the Geely ecosystem, helping Polestar manage liquidity while it pursues a dealer‑led commercial model and production diversification.

Numbers at a glance (Q3 & YTD 2025)

  • Q3 2025 revenue:$748M (↑36% YoY)
  • Q3 2025 net loss:$365M (vs. $323M loss a year ago)
  • Q3 2025 gross margin:(6.1%)
  • 9M 2025 revenue:$2.171B (↑48.8% YoY)
  • 9M 2025 gross margin:(34.5%) (impairment‑driven)
  • Conference call:14:00 CET today (investor webcast link via IR).

What’s next

  • Formal reverse‑split details (ratio, record date, effective date) and any PSNYW warrant adjustments are expected from Polestar.
  • Execution on margins: Watch tariff exposure, mix, discounting, residual‑value trends, and further cost‑out steps. Management characterized Q3 results as “disappointing,” highlighting the need for margin repair. Reuters
  • Listing clock: Progress toward sustained $1+ on the ADS will be critical before the April 29, 2026 compliance deadline.

FAQs

What is a reverse stock split?
A corporate action that reduces the number of outstanding shares while proportionally increasing the share price; it does not change a shareholder’s total economic stake. Polestar aims to use it to help retain Nasdaq listing.

Will PSNYW be affected?
Companies usually adjust warrant terms (exercise price/share count) to keep warrant economics neutral after a split. Polestar hasn’t yet disclosed the PSNYW specifics—monitor the official notice.

When is the earnings call?
2:00 p.m. CET today (Nov 12); details are posted on Polestar’s Investor Relations site.


Sources & further reading

  • Polestar Q3/9M 2025 update & reverse‑split plan (press release) — financials, liquidity, conference‑call details.
  • Reuters coverage of the results, reverse split, and early share move.
  • Nasdaq minimum bid‑price notice timeline (deadline April 29, 2026).
  • Live pricing: PSNYW and PSNY real‑time snapshots.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Leap Therapeutics (LPTX) Rebrands as “Cypherpunk,” Buys $50M in Zcash; Ticker to Change to CYPH on Nov. 13 — Q3 Results and New $200M ATM Filed (Nov. 12, 2025)
Previous Story

Leap Therapeutics (LPTX) Rebrands as “Cypherpunk,” Buys $50M in Zcash; Ticker to Change to CYPH on Nov. 13 — Q3 Results and New $200M ATM Filed (Nov. 12, 2025)

AMD Stock Soars on AI Partnerships – Is $300 Next?
Next Story

AMD Stock Today (Nov 12, 2025): Shares Surge as Wall Street Buys Into $100B Data‑Center Ambition and AI Roadmap

Go toTop